tiprankstipranks
Gyre: Last patient completes trial evaluating F351 for CHB-liver fibrosis
PremiumThe FlyGyre: Last patient completes trial evaluating F351 for CHB-liver fibrosis
3M ago
Gyre Therapeutics Welcomes Dr. Epstein to Leadership Team
Premium
Company Announcements
Gyre Therapeutics Welcomes Dr. Epstein to Leadership Team
6M ago
Catalyst Biosciences Inc trading resumes
Premium
The Fly
Catalyst Biosciences Inc trading resumes
6M ago
Gyre Therapeutics Advances with F230 IND Approval in China
PremiumCompany AnnouncementsGyre Therapeutics Advances with F230 IND Approval in China
8M ago
Gyre Therapeutics gets IND okay from China’s NMPA to evaluate F230 for PAH
Premium
The Fly
Gyre Therapeutics gets IND okay from China’s NMPA to evaluate F230 for PAH
8M ago
Gyre Therapeutics files $150M mixed securities shelf
Premium
The Fly
Gyre Therapeutics files $150M mixed securities shelf
8M ago
Gyre Therapeutics Expands Pulmonary Fibrosis Portfolio
PremiumCompany AnnouncementsGyre Therapeutics Expands Pulmonary Fibrosis Portfolio
9M ago
Gyre Therapeutics Welcomes New Expertise to Board Team
Premium
Company Announcements
Gyre Therapeutics Welcomes New Expertise to Board Team
11M ago
Gyre Therapeutics expands board of directors with appointment of Nussbaum
Premium
The Fly
Gyre Therapeutics expands board of directors with appointment of Nussbaum
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100